Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  ANGLE plc    AGL   GB0034330679

ANGLE PLC

(AGL)
  Report  
Delayed Quote. Delayed London Stock Exchange - 06/19 11:35:18 am
60.2 GBp   +0.33%
06/05ANGLE : Completion of Ovarian Cancer Pre-Study
PU
05/31ANGLE : Positive Results from FDA Clinical Study
PU
04/26ANGLE : Immune suppressor cells promote metastasis
PU
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
06/13/2019 06/14/2019 06/17/2019 06/18/2019 06/19/2019 Date
58(c) 55.6(c) 58.5(c) 60(c) 60.2(c) Last
103 851 166 725 759 494 299 239 86 665 Volume
-1.69% -4.14% +5.22% +2.56% +0.33% Change
More quotes
Financials (GBP)
Sales 2019 1,30 M
EBIT 2019 -10,3 M
Net income 2019 -8,60 M
Debt 2019 -
Yield 2019 -
Sales 2020 2,70 M
EBIT 2020 -9,80 M
Net income 2020 -8,70 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
Capi. / Sales2019 68,7x
Capi. / Sales2020 33,1x
Capitalization 89,2 M
More Financials
Company
ANGLE plc is a holding company. The Company's principal activity is undertaken in relation to the commercialization of its Parsortix cell separation system, with deployment in non-invasive cancer diagnostics. The Company is a specialist medical diagnostic company, which offers products for cancer... 
More about the company
Latest news on ANGLE PLC
06/05ANGLE : Completion of Ovarian Cancer Pre-Study
PU
05/31ANGLE : Positive Results from FDA Clinical Study
PU
04/26ANGLE : Immune suppressor cells promote metastasis
PU
04/18ANGLE : Parsortix used in new cancer assessment technique
PU
04/12ANGLE : Lung cancer study uses angle's parsortix system
PU
04/04ANGLE : Aacr 2019
PU
03/07ANGLE : Enrolment complete for fda clinical study
PU
02/28ANGLE : First subjects enrolled in ovarian cancer study
PU
02/25ANGLE : Customer demonstrates new use for parsortix
PU
02/11ANGLE : Research into role of immune cells in cancer
PU
More news
Analyst Recommendations on ANGLE PLC
More recommendations
Sector news : Bio Therapeutic Drugs
02:24pPFIZER : Fitch Puts Pfizer on Watch Negative, Notes Leverage Increase
DJ
09:05aGILEAD SCIENCES : Sets Collaboration With Nurix Therapeutics
DJ
06/18WHAT'S NEWS : Business & Finance -- WSJ
DJ
06/18PFIZER : Expands Cancer-Treatment Lineup
DJ
06/17ARRAY BIOPHARMA : Pfizer makes $10.6 billion cancer bet in cash deal for Array B..
RE
More sector news : Bio Therapeutic Drugs
Chart ANGLE PLC
Duration : Period :
ANGLE plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ANGLE PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
 
Mean consensus
Number of Analysts 0
Average target price 1,10  GBP
Spread / Average Target 77%
EPS Revisions
Managers
NameTitle
Andrew D. W. Newland Chief Executive Officer & Executive Director
Garth Robert Selvey Non-Executive Chairman
Martin Cooke Director-Operations & Regulatory Affairs
Ian Francis Griffiths CFO, Secretary & Executive director
Jay Lewington Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
ANGLE PLC54.36%132
GILEAD SCIENCES7.27%80 909
VERTEX PHARMACEUTICALS4.87%42 680
REGENERON PHARMACEUTICALS-16.74%32 744
GENMAB13.49%10 857
SAREPTA THERAPEUTICS INC21.25%8 523